Investors might want to bet on Arvinas, Inc. (ARVN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

Company Announcement - Arvinas, Inc announced the appointment of Jared Freedberg as General Counsel, bringing over 20 years of legal and commercial experience to the company [1] - Jared Freedberg's previous roles include General Counsel at Intercept Pharmaceuticals and Immunomedics, Inc, as well as Vice President, Legal, Business Development and Licensing at Mallinckrodt Pharmaceuticals [1] - The company granted Mr Freedberg an option to purchase 67,314 shares of common stock and a restricted stock unit award for 45,504 shares as part of his employment inducement [2] Executive Compensation - The stock option has a 10-year term with an exercise price of $38.10 per share, equal to the closing price on the grant date [3] - The option vests over four years, with 25% vesting after one year and the remainder vesting monthly thereafter [3] - The restricted stock units vest in four equal annual installments, contingent on continued employment [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC Discovery Engine platform [4] - The company has three clinical-stage programs: vepdegestrant (ARV-471) for ER+/HER2- breast cancer, and ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer [4] Strategic Focus - The company aims to advance its pipeline of earlier stage assets driven by the PROTAC protein degrader platform while preparing for potential product commercialization [1] - Arvinas is pioneering scientific advancements in protein degradation to improve treatment options for patients with serious diseases [2][4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 ________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 _______________ ...

Pioneering the future of targeted protein egradation therapeutics d Safe harbor and forward-looking statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...